Rapid autopsy maps lethal bladder cancer evolution in 20 patients

A peer-reviewed study of 104 tumors collected from 20 patients with advanced bladder cancer reconstructed the tumors’ evolutionary histories and found that metastatic tumors appeared to seed additional metastases and support the spread of more aggressive bladder cancer subtypes. Published in Nature, the rapid-autopsy study provides a patient-level view of how lethal metastatic bladder cancers develop across different subtypes and anatomical sites, although the small cohort limits how broadly the findings can be generalized. Researchers from Fred Hutchinson Cancer Center and the University of Washington used a rapid-autopsy program to collect samples from people with advanced bladder cancer, including rare subtypes that have been comparatively understudied.

The program allowed investigators to examine multiple tumors from the same patient and analyze the genomic architecture of the cancers, meaning the genes, DNA sequences and genetic variations that work together to shape biological traits and disease. By combining these data, the team inferred that the earliest metastatic tumor was likely the primary source for widespread later metastases. “The major driver of death from bladder cancer is metastasis, and in order to understand and target it we needed better data to learn about how the tumors migrate and spread,” said co-senior author Gavin Ha, PhD, of Fred Hutch’s Public Health Sciences Division.

Co-senior author Andrew Hsieh, MD, said the results suggest that metastases may serve as a staging point for further spread. These are evolutionary relationships inferred from tumor samples rather than direct observations of every route taken by individual cancer cells. The researchers also found distinct differences among bladder cancer subtypes, including differences in how the subtypes developed metastasis.

Importantly for noninvasive monitoring, they showed that the subtype differences could be captured in circulating DNA from blood. This finding indicates that blood-based DNA measurements can reflect genomic features that distinguish the cancer subtypes examined in the study. It does not by itself establish circulating DNA as a clinical test or demonstrate that monitoring it improves patient outcomes.

Hsieh said the team hopes to examine in subsequent research whether a single metastasis or residual metastatic disease could respond to more tailored therapies, but that question was not resolved by the present study. Several limitations define the scope of the findings. The study also focused on established metastatic disease rather than following bladder cancer continuously from its earliest primary stage, so it does not provide a complete natural history of the disease.

Its evolutionary sequences were reconstructed from genomic and sampling data, and it did not evaluate the effectiveness of a treatment strategy. A separate clinical study, the REINFORCE trial led by Martin Ma, is investigating whether consolidative treatment—radiation to the bladder or radical cystectomy, together with stereotactic body radiation therapy directed at all metastatic sites—can be administered safely and delay progression. The rapid-autopsy study supplies a detailed framework for that work by showing that metastatic sites can contribute to further dissemination and that lethal bladder cancer subtypes differ in their evolutionary patterns; whether the proposed treatment approach improves outcomes remains a question for the separate trial.

Subject of Research: Tumor evolution and subtype heterogeneity in advanced metastatic bladder cancer

Article Title: Study uncovers genomic architecture and natural history of metastatic bladder cancer

Article References: Study uncovers genomic architecture and natural history of metastatic bladder cancer. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: metastatic bladder cancer, rapid autopsy, tumor evolution, cancer genomics, circulating tumor DNA, molecular subtypes, metastasis, Fred Hutch, Nature, uncovers, genomic, architecture